Article info

Download PDFPDF
THU0306 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of The BCL-2 Inhibitor Venetoclax (ABT-199) in A Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus

Authors

Citation

Lu P, Fleischmann R, Curtis C, et al
THU0306 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of The BCL-2 Inhibitor Venetoclax (ABT-199) in A Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus

Publication history

  • First published July 15, 2016.
Online issue publication 
July 15, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.